TCGA-J2-A4AE-01A-21R-A24H-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.370
- TNFA_SIGNALING_VIA_NFKB+0.370
- INFLAMMATORY_RESPONSE+0.260
- BILE_ACID_METABOLISM+0.230
- KRAS_SIGNALING_UP+0.220
- IL6_JAK_STAT3_SIGNALING+0.210
- INTERFERON_GAMMA_RESPONSE+0.200
- COAGULATION+0.180
- ALLOGRAFT_REJECTION+0.170
- IL2_STAT5_SIGNALING+0.170
Top 10 suppressed
- MYC_TARGETS_V1-0.630
- MYC_TARGETS_V2-0.620
- OXIDATIVE_PHOSPHORYLATION-0.550
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.530
- G2M_CHECKPOINT-0.480
- UNFOLDED_PROTEIN_RESPONSE-0.470
- MTORC1_SIGNALING-0.460
- DNA_REPAIR-0.450
- PROTEIN_SECRETION-0.440
- E2F_TARGETS-0.430
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_DV86M0Y7 | pilocytic astrocytoma | — | 0.890 |
| 2 | TCGA-GV-A3QK-01B-11R-A23N-07 | — | — | 0.888 |
| 3 | BS_94MT16N2 | pilocytic astrocytoma | — | 0.885 |
| 4 | ee0e68bf-7fa0-4edc-a9df-30a63c2db34a | — | — | 0.879 |
| 5 | TCGA-E9-A3Q9-01A-11R-A21T-07 | — | B | 0.876 |
| 6 | MDT-AP-2296 | Med | Medulloblastoma | 0.875 |
| 7 | SRR1313642 | GTEX | — | 0.873 |
| 8 | TCGA-ZF-A9R7-01A-11R-A38B-07 | — | — | 0.873 |
| 9 | BS_21RE8W46 | pilocytic astrocytoma | — | 0.873 |
| 10 | SRR1331511 | GTEX | — | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.370 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.170 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.090 | Inavolisib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |